期刊
JOURNAL OF PARKINSONS DISEASE
卷 11, 期 3, 页码 1117-1127出版社
IOS PRESS
DOI: 10.3233/JPD-212535
关键词
Parkinson's disease; neurofilament light; Parkinson's progression markers initiative; cognition; tau
资金
- Shanghai Municipal Science and Technology Major Project [2018SHZDZX01]
- ZJLab
- StateKey Laboratory of Neurobiology and Frontiers Center for Brain Science of Ministry of Education, Fudan University
- Michael J Fox Foundation for Parkinson's Research
- AbbVie
- Allergan
- Avid Radiopharmaceuticals
- Biogen
- BioLegend
- Bristol-Myers Squibb
- Celgene
- Denali
- GE Healthcare
- Genentech
- GlaxoSmithKline
- Lilly
- Lundbeck
- Merck
- Meso Scale Discovery
- Pfizer
- Piramal
- Prevail Therapeutics
- Roche
- Sanofi Genzyme
- Servier
- Takeda
- Teva
- UCB
- Verily
- Voyager Therapeutics
- Golub Capital
- Tianqiao and Chrissy Chen Institute
The study found that serum NfL concentration can serve as an accessible biomarker for monitoring the severity and progression of cognitive decline in PD patients. Patients with PD had higher levels of serum NfL compared to healthy controls, and the increase in NfL levels was faster in the PD group. Baseline NfL levels and their rate of change were found to predict measurable cognitive decline in early PD, as well as future risk of PD dementia.
Background: Neurofilament light (NfL) can reflect the extent of neuron/axon damage, thus providing an opportunity to examine the severity and progression of the diseases with such damage. Objective: Whether serum NfL can be used as an indicator to monitor the cognitive progress of de novo Parkinson's disease (PD) remains unclear. Methods: In this research, 144 healthy controls and 301 de novo PD patients from Parkinson's Progression Markers Initiative (PPMI) were recruited. Linear mixed effects models were used to examine the associations of baseline/longitudinal serum NfL with cognitive decline. Cox regression was used to detect cognitive progression in PD participants. Results: We found PD patients had higher serum NfL than controls at baseline (p = 0.031), and NfL increase was faster in PD group (p < 0.001). Both baseline serum NfL and its rate of change predicted measurable cognitive decline in early PD (MoCA, beta = -0.014, p < 0.001; beta = -0.002, p < 0.001, respectively). Additionally, we observed that NfL levels were also able to predict progression in different diagnostic groups and Amyloid- PD and Amyloid+PD groups. After an average follow-up of 6.37 +/- 1.84 years, the baseline NfL of the third tertile of high concentrations was associated with a future high risk of PD dementia (adjusted HR 6.33, 95% CI 2.62-15.29, p < 0.001). Conclusion: In conclusion, our results indicated that the serum NfL concentration could function as an easily accessible biomarker to monitor the severity and progression of cognitive decline in PD.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据